BIO Hails Senate Passage of America Invents Act

BIO Hails Senate Passage of America Invents Act

Bipartisan, consensus-oriented approach will strengthen nation’s patent system and spur innovation, job creation

Washington, D.C. (March 8, 2011) – Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement on the passage today of the America Invents Act (S. 23) by the U.S. Senate:

“BIO commends the Senate for its overwhelming passage of the America Invents Act by a vote of 95-5.  We appreciate the dedication of Senate Judiciary Chairman Patrick Leahy (D-VT), Ranking Member Charles Grassley (R-IA) and the bill’s other cosponsors for their tireless efforts to build bipartisan consensus on the legislation.  Once enacted into law, it will strengthen and improve our nation’s patent system, spurring innovation and job creation.

“Patents are often the main assets of small biotech companies, and they rely on this intellectual property to attract investors to fund the lengthy and expensive research and development process necessary to bring breakthrough new therapies and other biotech products to patients and consumers.

“The improvements made by the America Invents Act would benefit all sectors of the U.S. economy by enhancing patent quality and the efficiency, objectivity, predictability, and transparency of the patent system. 

“BIO encourages the House of Representatives to consider patent reform without delay, and we look forward to working with Chairman Lamar Smith (R-TX) and the members of the House Committee on the Judiciary.  We are committed to ensuring that patent reform legislation preserves and enhances the incentives necessary to sustain our nation’s global leadership in biotechnology innovation and to spur the creation of high-wage, high-value jobs throughout the country.”

Advertisement

2011 BIO International Convention Super Sessions

2011 BIO International Convention Super Sessions Focus on State of the Industry

C-Level speakers lead broad conversations on global biotech, industry forecast, and key trends

WASHINGTON, D.C. (March 2, 2011) — The 2011 BIO International Convention will feature six high-level super sessions focused on the state of the industry, global biotech advancements and the outlook on the future of the industry. Hosted by the Biotechnology Industry Organization (BIO), the global event for biotechnology will take place June 27-30, 2011 at the Walter E. Washington Convention Center in Washington D.C.

“The last few years have presented significant economic challenges for emerging biotech companies trying to raise investment capital, which has had a global impact on the industry. Despite recent positive signs, it is still a tough market,” said BIO CEO and President Jim Greenwood. “These Super Sessions feature high-level speakers sharing their long-term outlook on the industry, and suggested strategies for successfully rebounding from the financial challenges and moving innovation forward to help heal, fuel and feed the world.”

Super Sessions include:

Ernst & Young’s 25th Annual Biotechnology Industry Report

Ernst & Young will present highlights from its 25th annual industry report. The session will discuss implications for biotech companies as they face a more uncertain future in the current business climate. As always, Ernst & Young will also summarize the sector’s performance using key metrics – financial performance, financing, deals and pipeline productivity.

Sponsored by: Ernst & Young 
Tuesday, June 28, Time: 10:00 am – 11:30 am
Confirmed Speakers: Glen Giovannetti, Partner and Global Biotech Leader, Ernst & Young LLP; Gautam Jaggi, Senior Manager and Editor, Beyond Borders and Progressions, Ernst & Young LLP

Burrill State-of-the-Industry Report
This presentation will look back over 25 years and describe some of the critical events that have shaped the industry into the global enterprise it is today and discuss what companies will need to do in order to remain competitive in a world being influenced by a tougher financial climate, rapidly evolving technology, globalization and new emerging markets.

Sponsored by: Burrill & Company
Tuesday, June 28, Time: 2:00 pm – 3:30 pm
Confirmed Speaker: G. Steven Burrill, Chief Executive Officer, Burrill & Company  

It Takes a Village– The Biotechnology Innovation Ecosystem

This session will detail the roles, relationships and interplay among government research labs, universities, and large and small biotechnology firms in the continuum from basic research to FDA-approved products and ultimately to the patient.

Sponsored by: Eli Lilly and Company
Tuesday, June 28, Time: 3:45 pm – 5:15 pm
Confirmed Speaker: John Lechleiter, Ph.D., Chairman, President & Chief Executive Officer, Eli Lilly & Company

Emerging Markets: The Future of Growth for Biologics?

This panel will bring together leading business executives with senior government officials to talk about how Emerging Markets are shaping business thinking and what impact they will have on the future of the biotech sector.

Sponsored by: Merck
Wednesday June 29, Time: 10:00 – 11:30 am
Confirmed Speaker: Richard T. Clark, Chairman, Merck

Campbell Alliance 2011 Dealmakers’ Intentions

Campbell Alliance and BIO present updated findings from two unique forward-looking measures of deal-making in the industry – the Campbell Alliance Dealmakers’ Intentions Survey and the BIO One-on-One Partnering Forecast.  New analysis in 2011 will include year-over-year trends and the first assessment of the predictive value of these instruments.

Sponsored by: Campbell Alliance
Wednesday June 29, Time: 2:00 – 3:30 pm
Speakers to be announced. 

Worldview 2011: Scientific American’s Regional Bio-Innovation Scorecard

Worldview 2011 will feature the third annual Scientific American’s Regional Bio-Innovation Scorecard, a review of individual country programs and policies aimed at growing local innovative biotechnology sectors. 

Wednesday June 29, Time: 3:45 – 5:15 pm
Confirmed Speaker: Fareed Zakaria, CNN host, Editor-at-Large of TIME Magazine, Washington Post columnist, former Editor, Newsweek International

The 2011 BIO International Convention is expected to draw more than 15,000 industry leaders from 49 states and 65 countries.  This year, the Convention program will feature more than 125 sessions in 16 tracks.  In addition, this year’s BIO Exhibition will cover an estimated 180,000 net sq. ft. and host more than 1,700 exhibitors.

The BIO International Convention also includes the BIO Business Forum, which offers attendees an unparalleled opportunity for large and small biotech companies to gather in one place, at one time to engage in partnering discussions. The ability to schedule up to 80 one-on-one meetings within just a few short days with biotech leaders from around the world enables companies to maximize their ROI for the registration and travel investment for this event. In 2010, the BIO Business Forum hosted more than 17,000 partnering meetings with more than 2,000 companies participating.

The BIO International Convention helps to support the association’s programs and initiatives. BIO works throughout the year to create a policy environment that enables the industry to continue to fulfill its vision of bettering the world through biotechnology innovation.  For additional attendee and exhibitor information, please visit http://convention.bio.org.

For detailed descriptions and a full program, please visit http://convention.bio.org.

Advance media registration for the 2011 BIO International Convention is now open and will be available online through June 17, 2011. To register in advance, please visit http://convention.bio.org/media.

BIO Press Release: Former British Prime Minister Tony Blair to Present a Keynote Address at 2011 BIO International Convention

Former British Prime Minister Tony Blair to Present a Keynote Address at 2011 BIO International Convention

 

Convention to take place June 27-30, 2011 in Washington, DC

 

WASHINGTON, D.C. – (January 31, 2011) – The Biotechnology Industry Organization (BIO) announced today that former British Prime Minister Tony Blair will participate in a keynote presentation at the 2011 BIO International Convention.  BIO President and CEO Jim Greenwood will host an “Interview with Tony Blair” during the keynote luncheon on Tuesday June 28, 2011. 

Hosted by BIO, the global event for biotechnology will take place June 27-30, 2011 at the Walter E. Washington Convention Center in Washington D.C.

“Mr. Blair is highly-regarded throughout the international community and we look forward to hearing his unique perspective on our industry at the 2011 BIO International Convention, the Global Event for Biotechnology,” said Greenwood.  “Mr. Blair’s vast experience as a global leader will provide our audience with helpful and inspirational insights as we continue our industry’s global mission to heal, fuel and feed the world.”

Mr. Blair served as Prime Minister of Great Britain and Northern Ireland from May 1997 through June 2007.  He was also the leader of Britain’s Labour Party (1994 to 2007) and the Member of Parliament for Sedgefield, England (1983 to 2007).

Following his term as Prime Minister, Mr. Blair served as the Quartet Representative to the Middle East. He represents the USA, UN, Russia and the EU, working with the Palestinians to prepare for statehood as part of the international community’s effort to secure peace.  He also launched the Tony Blair Faith Foundation to promote respect and understanding of and between the major religions and to make the case for faith as a force for good in the modern world.   He continues to be an advocate on the issues he cares about such as Africa and climate change.

Tuesday’s keynote luncheon is sponsored by Janssen Pharmaceutical Companies of Johnson & Johnson.
The 2011 BIO International Convention is expected to draw more than 15,000 industry leaders from 49 states and 65 countries.  This year, the Convention program will feature more than 125 sessions in 14 tracks.  In addition, this year’s BIO Exhibition will cover an estimated 180,000 net sq. ft. and host more than 1,700 exhibitors.

The BIO International Convention also includes the BIO Business Forum, which offers attendees an unparalleled opportunity for large and small biotech companies to gather in one place, at one time to engage in partnering discussions. The ability to schedule up to 80 one-on-one meetings within just a few short days with biotech leaders from around the world enables companies to maximize their ROI for the registration and travel investment for this event. In 2010, the BIO Business Forum hosted more than 17,000 partnering meetings with more than 2,000 companies participating.

The BIO International Convention helps to support the association’s programs and initiatives. BIO works throughout the year to create a policy environment that enables the industry to continue to fulfill its vision of bettering the world through biotechnology innovation.  For additional attendee and exhibitor information, please visit http://convention.bio.org.

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtech Now, an online portal and monthly newsletter chronicling “innovations transforming our world.” Subscribe to BIOtech Now.

Upcoming BIO Events


BIO CEO & Investor Conference
February 14-15, 2011
New York, NY

BIO-Europe Spring 2011
March 14-16, 2011
Milan, Italy

BIO Intellectual Property Counsels Committee Spring Conference and Committee Meeting
April 13-15, 2011
Seattle, WA

World Congress on Industrial Biotechnology & Bioprocessing
May 8-11, 2011
Toronto, Ontario, Canada

BIO International Convention
June 27-30, 2011
Washington, DC

2011 BIO Human Resources Conference
June 26-28, 2011
Washington, DC

BIO Supports Patent Reform Act of 2011: Press Release

BIO Supports Patent Reform Act of 2011

Bipartisan, consensus-oriented approach will strengthen nation’s patent system

 

Washington, D.C. (January 28, 2011) – Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following comment on the introduction of the Patent Reform Act of 2011 (S. 23) by Senate Judiciary Committee Chairman Patrick Leahy (D-VT) earlier this week:

“BIO appreciates the dedication of Chairman Leahy, Ranking Member Charles Grassley (R-IA) and the bill’s other cosponsors for their tireless efforts over the past several years to carefully craft bipartisan, consensus-oriented patent reform legislation.

“We believe the Patent Reform Act of 2011 will help strengthen and improve our nation’s patent system for all users while preserving the incentives necessary to spur the creation of high-wage, high-value jobs and sustain America’s global leadership in innovation.

“Innovation in biotechnology is based upon the strong and predictable protection of intellectual property provided by our nation’s patent system. Without strong and predictable patent protection, investors would shy away from investing hundreds of millions of dollars, over a decade or more, in high-risk biotechnology companies, and will simply put their money into projects or products that are less risky or offer a more immediate return but are of less value to society.

“The Patent Reform Act of 2011 would improve the patent system in ways that would benefit all sectors of the U.S. economy by enhancing patent quality and the efficiency, objectivity, predictability, and transparency of the patent system.  BIO remains steadfast in our commitment to work with the Chairman and members of the House and Senate as this legislation advances to ensure that the final bill remains true to these principles.”

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtech Now, an online portal and monthly newsletter chronicling “innovations transforming our world.” Subscribe to BIOtech Now.

Upcoming BIO Events

BIO CEO & Investor Conference
February 14-15, 2011
New York, NY

BIO-Europe Spring 2011
March 14-16, 2011
Milan, Italy

BIO Intellectual Property Counsels Committee Spring Conference and Committee Meeting
April 13-15, 2011
Seattle, WA

World Congress on Industrial Biotechnology & Bioprocessing
May 8-11
Toronto, Ontario, Canada

BIO International Convention
June 27-30, 2011
Washington, DC

2011 BIO Human Resources Conference
June 26-28, 2011
Washington, DC

Biotechnology and the State of the Union Address

The following was published in Politico’s Join the Debate.  Politico asked “What should Obama say in the State of the Union?”

 

Jim Greenwood Former Congressman (R-Pa.), President and CEO, Biotechnology Industry Organization :

 

The president’s State of the Union should, rightly, focus on jobs, particularly the need to create and fill new jobs to compete in an increasing competitive global marketplace. There’s no industry that better exemplifies the promise of job creation than biotechnology.

Today, the U.S. biotechnology sector employs more than 1.3 million workers in high-skill, high-wage jobs. Since 2001, our industry has added nearly 200,000 jobs. This is quite an accomplishment in the midst of a deep recession, and a sign that this industry can be a driver of economic growth. Quite literally we are just what the doctor – and president – has ordered.

Strong patent protection, balanced reimbursement policies, science-based regulations and other pro-innovation public policies will help our industry fulfill our promise. Through targeted policies such as the Therapeutic Discovery Project, which awarded tax credits to small cutting-edge biotech companies to support research and development efforts, the president can help spur continued medical innovation, grow American jobs and position our nation for continued leadership in the global marketplace.

AUTM Bayh-Dole 30th Anniversary Event

Association of University Technology Managers Press Release

Deerfield, IL — December 12, 2010 will mark the 30th anniversary of the Bayh-Dole Act. This legislation changed fundamentally the way America develops technologies from federally funded university research and effectively secured the country’s leadership position in innovation.

As a result of Bayh-Dole, more than 6,000 new U.S. companies formed from university technologies, approximately 5,000 new products are on the market, 153 new drugs, vaccines or in vitro devices are protecting public health, and in just nine years 279,000 new jobs were created as part of a $187 billion dollar impact on U.S. gross domestic product.

AUTM, joined by the American Council on Education, Association of American Universities, Association of Public and Land-grant Universities, and BIO, is celebrating the occasion with an event in Washington, DC on the morning of Wednesday, December 1. The first half of the event will be moderated by former Rep. Jim Greenwood, CEO of BIO (Biotechnology Industry Organization), and will include remarks from original congressional sponsors of the Act, such as Sen. Birch Bayh. Sen. Bayh and Rep. John Conyers will comment on the importance of maintaining Bayh-Dole to secure America’s leadership position in innovation for the future.

The second half of the event will be a panel discussion among business, university and policy leaders who will discuss the current impact of the Bayh-Dole Act and how to build upon the success of the Act going forward.

Members of the news media and the public are invited, and coverage of the event is welcome.  For more information about the event, contact Jodi Talley, AUTM Communications Director, at +1-847-559-0846 or jtalley@autm.net.

WHAT: Event to celebrate the 30^th Anniversary of the Bayh-Dole Act

DETAILS: Wednesday, Dec. 1, 10 a.m. to 12 p.m. at the Washington Convention Center, 801 Mt. Vernon Place, NW, Washington, DC, Room 140

FOR MORE INFORMATION: Visit http://www.B-D30.org 

                                                                      

 

About the Event Organizers

Founded in 1918, ACE (www.acenet.edu) is the major coordinating body for all the nation’s higher education institutions, representing more than 1,600 college and university presidents, and more than 200 related associations, nationwide.

The Association of American Universities (www.aau.edu) is an association of 61 U.S. and two Canadian research universities organized to develop and implement effective national and institutional policies supporting research and scholarship, graduate and professional education, undergraduate education, and public service in research universities.
Association of Public and Land-grant Universities (www.aplu.org) is an association of public research universities, land-grant institutions, and state university systems, founding in 1887. A۰P۰L۰U member campuses enroll more than 3.5 million undergraduate and 1.1 million graduate students, employ more than 645,000 faculty members, and conduct nearly two-thirds of all academic research, totaling more than $34 billion annually. As the nation’s oldest higher education association, A۰P۰L۰U is dedicated to excellence in learning, discovery and engagement.

The Association of University Technology Managers (www.autm.net) is a nonprofit organization with an international membership of more than 3,000 technology managers and business executives. AUTM members — managers of intellectual property, one of the most active growth sectors of the global economy —come from more than 300 universities, research institutions and teaching hospitals as well as numerous businesses and government organizations.

BIO (www.bio.org) represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.